Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR Cascade Inhibitors: How Mutations Can Result in Therapy Resistance and How to Overcome Resistance

Sorafenib in advanced hepatocellular carcinoma

Llovet, J. M., Ricci, S., Mazzaferro, V., Hilgard, P., Gane, E., Blanc, J.-F., de Oliveira, A. C., Santoro, A., Raoul, J.-L., Forner, A., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0708857 · Cited by 13,097

The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity

Barretina, J., Caponigro, G., Stransky, N., Venkatesan, K., Margolin, A. A., Kim, S., Wilson, C. J., Lehár, J., Kryukov, G. V., Sonkin, D., et al. (2012) · Nature · doi:10.1038/nature11003 · Cited by 7,950

Improved survival with vemurafenib in melanoma with BRAF V600E mutation

Chapman, P. B., Hauschild, A., Robert, C., Haanen, J. B., Ascierto, P., Larkin, J., Dummer, R., Garbe, C., Testori, A., Maio, M., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1103782 · Cited by 7,720

Targeting cancer cells by ROS-mediated mechanisms: a radical therapeutic approach?

Trachootham, D., Alexandre, J., & Huang, P. (2009) · Nature Reviews Drug Discovery · doi:10.1038/nrd2803 · Cited by 5,452

Sorafenib in Advanced Clear-Cell Renal-Cell Carcinoma

Escudier, B., Eisen, T., Stadler, W. M., Szczylik, C., Oudard, S., Siebels, M., Negrier, S., Chevreau, C., Solska, E., Desai, A. A., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa060655 · Cited by 4,802

BAY 43-9006 Exhibits Broad Spectrum Oral Antitumor Activity and Targets the RAF/MEK/ERK Pathway and Receptor Tyrosine Kinases Involved in Tumor Progression and Angiogenesis

Wilhelm, S. M., Carter, C., Tang, L., Wilkie, D., McNabola, A., Rong, H., Chen, C., Zhang, X., Vincent, P., McHugh, M., et al. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-1443 · Cited by 4,017

AMPK Phosphorylation of Raptor Mediates a Metabolic Checkpoint

Gwinn, D. M., Shackelford, D. B., Egan, D. F., Mihaylova, M. M., Mery, A., Vasquez, D. S., Turk, B. E., & Shaw, R. J. (2008) · Molecular Cell · doi:10.1016/j.molcel.2008.03.003 · Cited by 3,849

A specific inhibitor of phosphatidylinositol 3-kinase, 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one (LY294002).

Vlahos, C. J., Matter, W. F., Hui, K. Y., & Brown, R. F. (1994) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(17)37680-9 · Cited by 3,240

Inhibition of Mutated, Activated BRAF in Metastatic Melanoma

Flaherty, K. T., Puzanov, I., Kim, K. B., Ribas, A., McArthur, G. A., Sosman, J. A., O'Dwyer, P. J., Lee, R. J., Grippo, J. F., Nolop, K., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1002011 · Cited by 3,103

Systematic identification of genomic markers of drug sensitivity in cancer cells

Garnett, M. J., Edelman, E. J., Heidorn, S. J., Greenman, C. D., Dastur, A., Lau, K. W., Greninger, P., Thompson, I. R., Luo, X., Soares, J., et al. (2012) · Nature · doi:10.1038/nature11005 · Cited by 2,456

Renal-Cell Carcinoma

Motzer, R. J., Bander, N. H., & Nanus, D. M. (1996) · New England Journal of Medicine · doi:10.1056/nejm199609193351207 · Cited by 2,219

Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation

Nazarian, R., Shi, H., Wang, Q., Kong, X., Koya, R. C., Lee, H., Chen, Z., Lee, M.-K., Attar, N., Sazegar, H., et al. (2010) · Nature · doi:10.1038/nature09626 · Cited by 2,192

Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib

Sosman, J. A., Kim, K. B., Schuchter, L., Gonzalez, R., Pavlick, A. C., Weber, J. S., McArthur, G. A., Hutson, T. E., Moschos, S. J., Flaherty, K. T., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1112302 · Cited by 2,156

The LKB1-AMPK pathway: metabolism and growth control in tumour suppression

Shackelford, D. B., & Shaw, R. J. (2009) · Nature Reviews Cancer · doi:10.1038/nrc2676 · Cited by 1,943

The functions and regulation of the PTEN tumour suppressor

Song, M. S., Salmena, L., & Pandolfi, P. P. (2012) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm3330 · Cited by 1,926

Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma

Bollag, G., Hirth, P., Tsai, J., Zhang, J., Ibrahim, P. N., Cho, H., Spevak, W., Zhang, C., Zhang, Y., Habets, G., et al. (2010) · Nature · doi:10.1038/nature09454 · Cited by 1,831

RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF

Poulikakos, P. I., Zhang, C., Bollag, G., Shokat, K. M., & Rosen, N. (2010) · Nature · doi:10.1038/nature08902 · Cited by 1,811

Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion

Straussman, R., Morikawa, T., Shee, K., Barzily-Rokni, M., Qian, Z. R., Du, J., Davis, A., Mongare, M. M., Gould, J., Frederick, D. T., et al. (2012) · Nature · doi:10.1038/nature11183 · Cited by 1,771

Rapamycin inhibits primary and metastatic tumor growth by antiangiogenesis: involvement of vascular endothelial growth factor

Guba, M., von Breitenbuch, P., Steinbauer, M., Koehl, G., Flegel, S., Hornung, M., Bruns, C. J., Zuelke, C., Farkas, S., Anthuber, M., et al. (2002) · Nature Medicine · doi:10.1038/nm0202-128 · Cited by 1,739

Renal cell carcinoma

Rini, B. I., Campbell, S. C., & Escudier, B. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60229-4 · Cited by 1,621

Ubiquitination of hypoxia-inducible factor requires direct binding to the β-domain of the von Hippel–Lindau protein

Ohh, M., Park, C. W., Ivan, M., Hoffman, M. A., Kim, T.-Y., Huang, L. E., Pavletich, N., Chau, V., & Kaelin, W. G. (2000) · Nature Cell Biology · doi:10.1038/35017054 · Cited by 1,577

Kinase-Dead BRAF and Oncogenic RAS Cooperate to Drive Tumor Progression through CRAF

Heidorn, S. J., Milagre, C., Whittaker, S., Nourry, A., Niculescu-Duvas, I., Dhomen, N., Hussain, J., Reis-Filho, J. S., Springer, C. J., Pritchard, C., et al. (2010) · Cell · doi:10.1016/j.cell.2009.12.040 · Cited by 1,465

COT drives resistance to RAF inhibition through MAP kinase pathway reactivation

Johannessen, C. M., Boehm, J. S., Kim, S. Y., Thomas, S. R., Wardwell, L., Johnson, L. A., Emery, C. M., Stransky, N., Cogdill, A. P., Barretina, J., et al. (2010) · Nature · doi:10.1038/nature09627 · Cited by 1,460

RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E)

Poulikakos, P. I., Persaud, Y., Janakiraman, M., Kong, X., Ng, C., Moriceau, G., Shi, H., Atefi, M., Titz, B., Gabay, M. T., et al. (2011) · Nature · doi:10.1038/nature10662 · Cited by 1,454

Inhibition of mTORC1 leads to MAPK pathway activation through a PI3K-dependent feedback loop in human cancer

Carracedo, A., Ma, L., Teruya-Feldstein, J., Rojo, F., Salmena, L., Alimonti, A., Egia, A., Sasaki, A. T., Thomas, G., Kozma, S. C., et al. (2008) · Journal of Clinical Investigation · doi:10.1172/jci34739 · Cited by 1,381

Regorafenib (BAY 73‐4506): A new oral multikinase inhibitor of angiogenic, stromal and oncogenic receptor tyrosine kinases with potent preclinical antitumor activity

Wilhelm, S. M., Dumas, J., Adnane, L., Lynch, M., Carter, C. A., Schütz, G., Thierauch, K., & Zopf, D. (2011) · International Journal of Cancer · doi:10.1002/ijc.25864 · Cited by 1,355

Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activity

Tsai, J., Lee, J. T., Wang, W., Zhang, J., Cho, H., Mamo, S., Bremer, R., Gillette, S., Kong, J., Haass, N. K., et al. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0711741105 · Cited by 1,346

Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancers

Engelman, J. A., Chen, L., Tan, X., Crosby, K., Guimaraes, A. R., Upadhyay, R., Maira, M., McNamara, K., Perera, S. A., Song, Y., et al. (2008) · Nature Medicine · doi:10.1038/nm.1890 · Cited by 1,330

BRAF mutation predicts sensitivity to MEK inhibition

Solit, D. B., Garraway, L. A., Pratilas, C. A., Sawai, A., Getz, G., Basso, A., Ye, Q., Lobo, J. M., She, Y., Osman, I., et al. (2006) · Nature · doi:10.1038/nature04304 · Cited by 1,328

The translational landscape of mTOR signalling steers cancer initiation and metastasis

Hsieh, A. C., Liu, Y., Edlind, M. P., Ingolia, N. T., Janes, M. R., Sher, A., Shi, E. Y., Stumpf, C. R., Christensen, C., Bonham, M. J., et al. (2012) · Nature · doi:10.1038/nature10912 · Cited by 1,313

Acquired Resistance to BRAF Inhibitors Mediated by a RAF Kinase Switch in Melanoma Can Be Overcome by Cotargeting MEK and IGF-1R/PI3K

Villanueva, J., Vultur, A., Lee, J. T., Somasundaram, R., Fukunaga-Kalabis, M., Cipolla, A. K., Wubbenhorst, B., Xu, X., Gimotty, P. A., Kee, D., et al. (2010) · Cancer Cell · doi:10.1016/j.ccr.2010.11.023 · Cited by 1,259

Widespread potential for growth-factor-driven resistance to anticancer kinase inhibitors

Wilson, T. R., Fridlyand, J., Yan, Y., Penuel, E., Burton, L., Chan, E., Peng, J., Lin, E., Wang, Y., Sosman, J., et al. (2012) · Nature · doi:10.1038/nature11249 · Cited by 1,134

Identification and characterization of NVP-BEZ235, a new orally available dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor with potent in vivo antitumor activity

Maira, S.-M., Stauffer, F., Brueggen, J., Furet, P., Schnell, C., Fritsch, C., Brachmann, S., Chène, P., De Pover, A., Schoemaker, K., et al. (2008) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-08-0017 · Cited by 1,134

RAS Mutations in Cutaneous Squamous-Cell Carcinomas in Patients Treated with BRAF Inhibitors

Su, F., Viros, A., Milagre, C., Trunzer, K., Bollag, G., Spleiss, O., Reis-Filho, J. S., Kong, X., Koya, R. C., Flaherty, K. T., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1105358 · Cited by 1,038

Phase II Placebo-Controlled Randomized Discontinuation Trial of Sorafenib in Patients With Metastatic Renal Cell Carcinoma

Ratain, M. J., Eisen, T., Stadler, W. M., Flaherty, K. T., Kaye, S. B., Rosner, G. L., Gore, M., Desai, A. A., Patnaik, A., Xiong, H. Q., et al. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.03.6723 · Cited by 1,032

BRAF Mutations in Hairy-Cell Leukemia

Tiacci, E., Trifonov, V., Schiavoni, G., Holmes, A., Kern, W., Martelli, M. P., Pucciarini, A., Bigerna, B., Pacini, R., Wells, V. A., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1014209 · Cited by 1,024

Dissecting Therapeutic Resistance to RAF Inhibition in Melanoma by Tumor Genomic Profiling

Wagle, N., Emery, C., Berger, M. F., Davis, M. J., Sawyer, A., Pochanard, P., Kehoe, S. M., Johannessen, C. M., MacConaill, L. E., Hahn, W. C., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.33.2312 · Cited by 1,005

Rapamycin passes the torch: a new generation of mTOR inhibitors

Benjamin, D., Colombi, M., Moroni, C., & Hall, M. N. (2011) · Nature Reviews Drug Discovery · doi:10.1038/nrd3531 · Cited by 989

mTOR inhibition reverses Akt-dependent prostate intraepithelial neoplasia through regulation of apoptotic and HIF-1-dependent pathways

Majumder, P. K., Febbo, P. G., Bikoff, R., Berger, R., Xue, Q., McMahon, L. M., Manola, J., Brugarolas, J., McDonnell, T. J., Golub, T. R., et al. (2004) · Nature Medicine · doi:10.1038/nm1052 · Cited by 964

Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: a phase 1 dose-escalation trial

Falchook, G. S., Long, G. V., Kurzrock, R., Kim, K. B., Arkenau, T. H., Brown, M. P., Hamid, O., Infante, J. R., Millward, M., Pavlick, A. C., et al. (2012) · The Lancet · doi:10.1016/s0140-6736(12)60398-5 · Cited by 943

MK-2206, an Allosteric Akt Inhibitor, Enhances Antitumor Efficacy by Standard Chemotherapeutic Agents or Molecular Targeted Drugs In vitro and In vivo

Hirai, H., Sootome, H., Nakatsuru, Y., Miyama, K., Taguchi, S., Tsujioka, K., Ueno, Y., Hatch, H., Majumder, P. K., Pan, B.-S., et al. (2010) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-09-1012 · Cited by 860

AZD8055 Is a Potent, Selective, and Orally Bioavailable ATP-Competitive Mammalian Target of Rapamycin Kinase Inhibitor with In vitro and In vivo Antitumor Activity

Chresta, C. M., Davies, B. R., Hickson, I., Harding, T., Cosulich, S., Critchlow, S. E., Vincent, J. P., Ellston, R., Jones, D., Sini, P., et al. (2010) · Cancer Research · doi:10.1158/0008-5472.can-09-1751 · Cited by 812

CAL-101, a p110δ selective phosphatidylinositol-3-kinase inhibitor for the treatment of B-cell malignancies, inhibits PI3K signaling and cellular viability

Lannutti, B. J., Meadows, S. A., Herman, S. E. M., Kashishian, A., Steiner, B., Johnson, A. J., Byrd, J. C., Tyner, J. W., Loriaux, M. M., Deininger, M., et al. (2011) · Blood · doi:10.1182/blood-2010-03-275305 · Cited by 720

Activation of the PTEN/mTOR/STAT3 pathway in breast cancer stem-like cells is required for viability and maintenance

Zhou, J., Wulfkuhle, J., Zhang, H., Gu, P., Yang, Y., Deng, J., Margolick, J. B., Liotta, L. A., Petricoin, E., & Zhang, Y. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0702596104 · Cited by 698

Phase I, Dose-Escalation Study of BKM120, an Oral Pan-Class I PI3K Inhibitor, in Patients With Advanced Solid Tumors

Bendell, J. C., Rodon, J., Burris, H. A., de Jonge, M., Verweij, J., Birle, D., Demanse, D., De Buck, S. S., Ru, Q. C., Peters, M., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.36.1360 · Cited by 684

Wortmannin Inactivates Phosphoinositide 3-Kinase by Covalent Modification of Lys-802, a Residue Involved in the Phosphate Transfer Reaction

Wymann, M. P., Bulgarelli-Leva, G., Zvelebil, M. J., Pirola, L., Vanhaesebroeck, B., Waterfield, M. D., & Panayotou, G. (1996) · Molecular and Cellular Biology · doi:10.1128/mcb.16.4.1722 · Cited by 682

Sorafenib in advanced melanoma: a Phase II randomised discontinuation trial analysis

Eisen, T., Ahmad, T., Flaherty, K. T., Gore, M., Kaye, S., Marais, R., Gibbens, I., Hackett, S., James, M., Schuchter, L. M., et al. (2006) · British Journal of Cancer · doi:10.1038/sj.bjc.6603291 · Cited by 644

Melanoma whole-exome sequencing identifies V600EB-RAF amplification-mediated acquired B-RAF inhibitor resistance

Shi, H., Moriceau, G., Kong, X., Lee, M.-K., Lee, H., Koya, R. C., Ng, C., Chodon, T., Scolyer, R. A., Dahlman, K. B., et al. (2012) · Nature Communications · doi:10.1038/ncomms1727 · Cited by 640

A dual PI3 kinase/mTOR inhibitor reveals emergent efficacy in glioma

Fan, Q.-W., Knight, Z. A., Goldenberg, D. D., Yu, W., Mostov, K. E., Stokoe, D., Shokat, K. M., & Weiss, W. A. (2006) · Cancer Cell · doi:10.1016/j.ccr.2006.03.029 · Cited by 585

Cancer risk in diabetic patients treated with metformin: a systematic review and meta-analysis

Noto, H., Goto, A., Tsujimoto, T., & Noda, M. (2012) · PLoS ONE · doi:10.1371/journal.pone.0033411 · Cited by 566

Roles of the Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR pathways in controlling growth and sensitivity to therapy-implications for cancer and aging

Steelman, L. S., Chappell, W. H., Abrams, S. L., Kempf, C. R., Long, J., Laidler, P., Mijatovic, S., Maksimovic-Ivanic, D., Stivala, F., Mazzarino, M. C., et al. (2011) · Aging · doi:10.18632/aging.100296 · Cited by 553

PTEN Loss Confers BRAF Inhibitor Resistance to Melanoma Cells through the Suppression of BIM Expression

Paraiso, K. H. T., Xiang, Y., Rebecca, V. W., Abel, E. V., Chen, Y. A., Munko, A. C., Wood, E., Fedorenko, I. V., Sondak, V. K., Anderson, A. R. A., et al. (2011) · Cancer Research · doi:10.1158/0008-5472.can-10-2954 · Cited by 551

Identification and Characterization of NVP-BKM120, an Orally Available Pan-Class I PI3-Kinase Inhibitor

Maira, S.-M., Pecchi, S., Huang, A., Burger, M., Knapp, M., Sterker, D., Schnell, C., Guthy, D., Nagel, T., Wiesmann, M., et al. (2012) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-11-0474 · Cited by 529

Phase II Trial of Single-Agent Temsirolimus (CCI-779) for Relapsed Mantle Cell Lymphoma

Witzig, T. E., Geyer, S. M., Ghobrial, I., Inwards, D. J., Fonseca, R., Kurtin, P., Ansell, S. M., Luyun, R., Flynn, P. J., Morton, R. F., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.13.466 · Cited by 514

Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR inhibitors: rationale and importance to inhibiting these pathways in human health

Chappell, W. H., Steelman, L. S., Long, J. M., Kempf, R. C., Abrams, S. L., Franklin, R. A., Bäsecke, J., Stivala, F., Donia, M., Fagone, P., et al. (2011) · Oncotarget · doi:10.18632/oncotarget.240 · Cited by 510

Elevated CRAF as a Potential Mechanism of Acquired Resistance to BRAF Inhibition in Melanoma

Montagut, C., Sharma, S. V., Shioda, T., McDermott, U., Ulman, M., Ulkus, L. E., Dias-Santagata, D., Stubbs, H., Lee, D. Y., Singh, A., et al. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-6787 · Cited by 508

Drug discovery approaches targeting the PI3K/Akt pathway in cancer

Garcia-Echeverria, C., & Sellers, W. R. (2008) · Oncogene · doi:10.1038/onc.2008.246 · Cited by 473

In vivo Antitumor Activity of MEK and Phosphatidylinositol 3-Kinase Inhibitors in Basal-Like Breast Cancer Models

Hoeflich, K. P., O'Brien, C., Boyd, Z., Cavet, G., Guerrero, S., Jung, K., Januario, T., Savage, H., Punnoose, E., Truong, T., et al. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-0317 · Cited by 463

Exploring the specificity of the PI3K family inhibitor LY294002

Gharbi, S. I., Zvelebil, M. J., Shuttleworth, S. J., Hancox, T., Saghir, N., Timms, J. F., & Waterfield, M. D. (2007) · Biochemical Journal · doi:10.1042/bj20061489 · Cited by 462

Ku-0063794 is a specific inhibitor of the mammalian target of rapamycin (mTOR)

García-Martínez, J. M., Moran, J., Clarke, R. G., Gray, A., Cosulich, S. C., Chresta, C. M., & Alessi, D. R. (2009) · Biochemical Journal · doi:10.1042/bj20090489 · Cited by 455

PI3K Pathway Activation Mediates Resistance to MEK Inhibitors in KRAS Mutant Cancers

Wee, S., Jagani, Z., Xiang, K. X., Loo, A., Dorsch, M., Yao, Y.-M., Sellers, W. R., Lengauer, C., & Stegmeier, F. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-4765 · Cited by 455

The RAF inhibitor PLX4032 inhibits ERK signaling and tumor cell proliferation in a V600E BRAF-selective manner

Joseph, E. W., Pratilas, C. A., Poulikakos, P. I., Tadi, M., Wang, W., Taylor, B. S., Halilovic, E., Persaud, Y., Xing, F., Viale, A., et al. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1008990107 · Cited by 449

Autophagy in cancer associated fibroblasts promotes tumor cell survival: Role of hypoxia, HIF1 induction and NFκB activation in the tumor stromal microenvironment

Martinez-Outschoorn, U. E., Trimmer, C., Lin, Z., Whitaker-Menezes, D., Chiavarina, B., Zhou, J., Wang, C., Pavlides, S., Martinez-Cantarin, M. P., Capozza, F., et al. (2010) · Cell Cycle · doi:10.4161/cc.9.17.12928 · Cited by 408

Perifosine, a novel alkylphospholipid, inhibits protein kinase B activation.

Kondapaka, S. B., Singh, S. S., Dasmahapatra, G. P., Sausville, E. A., & Roy, K. (2003) · PubMed · Cited by 407

AZD6244 (ARRY-142886), a potent inhibitor of mitogen-activated protein kinase/extracellular signal-regulated kinase kinase 1/2 kinases: mechanism of action in vivo , pharmacokinetic/pharmacodynamic relationship, and potential for combination in preclinical models

Davies, B. R., Logie, A., McKay, J. S., Martin, P., Steele, S., Jenkins, R., Cockerill, M., Cartlidge, S., & Smith, P. D. (2007) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-07-0231 · Cited by 387

RAS Mutations Are Associated With the Development of Cutaneous Squamous Cell Tumors in Patients Treated With RAF Inhibitors

Oberholzer, P. A., Kee, D., Dziunycz, P., Sucker, A., Kamsukom, N., Jones, R., Roden, C., Chalk, C. J., Ardlie, K., Palescandolo, E., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.36.7680 · Cited by 386

Rheb Activates mTOR by Antagonizing Its Endogenous Inhibitor, FKBP38

Bai, X., Ma, D., Liu, A., Shen, X., Wang, Q. J., Liu, Y., & Jiang, Y. (2007) · Science · doi:10.1126/science.1147379 · Cited by 382

Akt/Protein Kinase B Signaling Inhibitor-2, a Selective Small Molecule Inhibitor of Akt Signaling with Antitumor Activity in Cancer Cells Overexpressing Akt

Yang, L., Dan, H. C., Sun, M., Liu, Q., Sun, X.-M., Feldman, R. I., Hamilton, A. D., Polokoff, M., Nicosia, S. V., Herlyn, M., et al. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-0343 · Cited by 371

Combinations of BRAF, MEK, and PI3K/mTOR Inhibitors Overcome Acquired Resistance to the BRAF Inhibitor GSK2118436 Dabrafenib, Mediated by NRAS or MEK Mutations

Greger, J. G., Eastman, S. D., Zhang, V., Bleam, M. R., Hughes, A. M., Smitheman, K. N., Dickerson, S. H., Laquerre, S. G., Liu, L., & Gilmer, T. M. (2012) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-11-0989 · Cited by 363

Ketones and lactate increase cancer cell “stemness,” driving recurrence, metastasis and poor clinical outcome in breast cancer: Achieving personalized medicine via Metabolo-Genomics

Martinez-Outschoorn, U. E., Prisco, M., Ertel, A., Tsirigos, A., Lin, Z., Pavlides, S., Wang, C., Flomenberg, N., Knudsen, E. S., Howell, A., et al. (2011) · Cell Cycle · doi:10.4161/cc.10.8.15330 · Cited by 338

Metformin Inhibits Cell Proliferation, Migration and Invasion by Attenuating CSC Function Mediated by Deregulating miRNAs in Pancreatic Cancer Cells

Bao, B., Wang, Z., Ali, S., Ahmad, A., Azmi, A. S., Sarkar, S. H., Banerjee, S., Kong, D., Li, Y., Thakur, S., et al. (2012) · Cancer Prevention Research · doi:10.1158/1940-6207.capr-11-0299 · Cited by 337

FTY720, a new alternative for treating blast crisis chronic myelogenous leukemia and Philadelphia chromosome–positive acute lymphocytic leukemia

Neviani, P., Santhanam, R., Oaks, J. J., Eiring, A. M., Notari, M., Blaser, B. W., Liu, S., Trotta, R., Muthusamy, N., Gambacorti-Passerini, C., et al. (2007) · Journal of Clinical Investigation · doi:10.1172/jci31095 · Cited by 335

Molecular pharmacology and antitumor activity of PX-866, a novel inhibitor of phosphoinositide-3-kinase signaling

Ihle, N. T., Williams, R., Chow, S., Chew, W., Berggren, M. I., Paine-Murrieta, G., Minion, D. J., Halter, R. J., Wipf, P., Abraham, R., et al. (2004) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.763.3.7 · Cited by 313

Increased cyclin D1 expression can mediate BRAF inhibitor resistance in BRAF V600E–mutated melanomas

Smalley, K. S. M., Lioni, M., Palma, M. D., Xiao, M., Desai, B., Egyhazi, S., Hansson, J., Wu, H., King, A. J., Van Belle, P., et al. (2008) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-08-0431 · Cited by 309

Dissociation of raptor from mTOR is a mechanism of rapamycin‐induced inhibition of mTOR function

Oshiro, N., Yoshino, K., Hidayat, S., Tokunaga, C., Hara, K., Eguchi, S., Avruch, J., & Yonezawa, K. (2004) · Genes to Cells · doi:10.1111/j.1356-9597.2004.00727.x · Cited by 308

Mutations and Deregulation of Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR Cascades Which Alter Therapy Response.

McCubrey, J. A., Steelman, L. S., Chappell, W. H., Abrams, S. L., Montalto, G., Cervello, M., Nicoletti, F., Fagone, P., Malaponte, G., Mazzarino, M. C., et al. (2012) · Oncotarget · doi:10.18632/oncotarget.652 · Cited by 306

Multi-Institutional Phase II Study of Selumetinib in Patients With Metastatic Biliary Cancers

Bekaii-Saab, T., Phelps, M. A., Li, X., Saji, M., Goff, L., Kauh, J. S. W., O'Neil, B. H., Balsom, S., Balint, C., Liersemann, R., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.33.9473 · Cited by 303

Metformin: Multi-faceted protection against cancer

Del Barco, S., Vazquez-Martin, A., Cufí, S., Oliveras-Ferraros, C., Bosch-Barrera, J., Joven, J., Martin-Castillo, B., & Menendez, J. A. (2011) · Oncotarget · doi:10.18632/oncotarget.387 · Cited by 302

Characterization of an Akt Kinase Inhibitor with Potent Pharmacodynamic and Antitumor Activity

Rhodes, N., Heerding, D. A., Duckett, D. R., Eberwein, D. J., Knick, V. B., Lansing, T. J., McConnell, R. T., Gilmer, T. M., Zhang, S.-Y., Robell, K., et al. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-5783 · Cited by 295

The p110δ structure: mechanisms for selectivity and potency of new PI(3)K inhibitors

Berndt, A., Miller, S., Williams, O., Le, D. D., Houseman, B. T., Pacold, J. I., Gorrec, F., Hon, W.-C., Ren, P., Liu, Y., et al. (2010) · Nature Chemical Biology · doi:10.1038/nchembio.293 · Cited by 292

If Started Early in Life, Metformin Treatment Increases Life Span and Postpones Tumors in Female SHR Mice

Anisimov, V. N., Berstein, L. M., Popovich, I. G., Zabezhinski, M. A., Egormin, P. A., Piskunova, T. S., Semenchenko, A. V., Tyndyk, M. L., Yurova, M. N., Kovalenko, I. G., et al. (2011) · Aging · doi:10.18632/aging.100273 · Cited by 285

Phase I/II study of GSK2118436, a selective inhibitor of oncogenic mutant BRAF kinase, in patients with metastatic melanoma and other solid tumors.

Kefford, R., Arkenau, H., Brown, M. P., Millward, M., Infante, J. R., Long, G. V., Ouellet, D., Curtis, M., Lebowitz, P. F., & Falchook, G. S. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2010.28.15_suppl.8503 · Cited by 275

Mechanisms of chemotherapy-induced human ovarian aging: double strand DNA breaks and microvascular compromise

Soleimani, R., Heytens, E., Darzynkiewicz, Z., & Oktay, K. (2011) · Aging · doi:10.18632/aging.100363 · Cited by 274

Development of Farnesyl Transferase Inhibitors: A Review

Appels, N. M. G. M., Beijnen, J. H., & Schellens, J. H. M. (2005) · The Oncologist · doi:10.1634/theoncologist.10-8-565 · Cited by 272

Drugging the PI3 Kinome: From Chemical Tools to Drugs in the Clinic

Workman, P., Clarke, P. A., Raynaud, F. I., & van Montfort, R. L. M. (2010) · Cancer Research · doi:10.1158/0008-5472.can-09-4355 · Cited by 264

Roles of the Ras/Raf/MEK/ERK pathway in leukemia therapy

Steelman, L. S., Franklin, R. A., Abrams, S. L., Chappell, W., Kempf, C. R., Bäsecke, J., Stivala, F., Donia, M., Fagone, P., Nicoletti, F., et al. (2011) · Leukemia · doi:10.1038/leu.2011.66 · Cited by 261

MicroRNA expression analysis in triple-negative (ER, PR and Her2/neu) breast cancer

Radojicic, J., Zaravinos, A., Vrekoussis, T., Kafousi, M., Spandidos, D. A., & Stathopoulos, E. N. (2011) · Cell Cycle · doi:10.4161/cc.10.3.14754 · Cited by 256

Genetic Predictors of MEK Dependence in Non–Small Cell Lung Cancer

Pratilas, C. A., Hanrahan, A. J., Halilovic, E., Persaud, Y., Soh, J., Chitale, D., Shigematsu, H., Yamamoto, H., Sawai, A., Janakiraman, M., et al. (2008) · Cancer Research · doi:10.1158/0008-5472.can-08-2223 · Cited by 255

Phase I Pharmacokinetic and Pharmacodynamic Study of the Oral MAPK/ERK Kinase Inhibitor PD-0325901 in Patients with Advanced Cancers

LoRusso, P. M., Krishnamurthi, S. S., Rinehart, J. J., Nabell, L. M., Malburg, L., Chapman, P. B., DePrimo, S. E., Bentivegna, S., Wilner, K. D., Tan, W., et al. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-1883 · Cited by 252

A STAT3-mediated metabolic switch is involved in tumour transformation and STAT3 addiction

Demaria, M., Giorgi, C., Lebiedzinska, M., Esposito, G., D'Angeli, L., Bartoli, A., Gough, D. J., Turkson, J., Levy, D. E., Watson, C. J., et al. (2010) · Aging · doi:10.18632/aging.100232 · Cited by 250

Mutant BRAF Melanomas—Dependence and Resistance

Poulikakos, P. I., & Rosen, N. (2011) · Cancer Cell · doi:10.1016/j.ccr.2011.01.008 · Cited by 250

Phase II Study of the Mammalian Target of Rapamycin Inhibitor Ridaforolimus in Patients With Advanced Bone and Soft Tissue Sarcomas

Chawla, S. P., Staddon, A. P., Baker, L. H., Schuetze, S. M., Tolcher, A. W., D'Amato, G. Z., Blay, J.-Y., Mita, M. M., Sankhala, K. K., Berk, L., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.35.6329 · Cited by 246

Glutaminolysis: Supplying carbon or nitrogen or both for cancer cells?

Dang, C. V. (2010) · Cell Cycle · doi:10.4161/cc.9.19.13302 · Cited by 245

Essential role for the p110 isoform in phosphoinositide 3-kinase activation and cell proliferation in acute myeloid leukemia

Sujobert, P. (2005) · Blood · doi:10.1182/blood-2004-08-3225 · Cited by 245

The Mitogen-Activated Protein/Extracellular Signal-Regulated Kinase Kinase Inhibitor AZD6244 (ARRY-142886) Induces Growth Arrest in Melanoma Cells and Tumor Regression When Combined with Docetaxel

Haass, N. K., Sproesser, K., Nguyen, T. K., Contractor, R., Medina, C. A., Nathanson, K. L., Herlyn, M., & Smalley, K. S. M. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-1440 · Cited by 244

Intermittent Administration of MEK Inhibitor GDC-0973 plus PI3K Inhibitor GDC-0941 Triggers Robust Apoptosis and Tumor Growth Inhibition

Hoeflich, K. P., Merchant, M., Orr, C., Chan, J., Den Otter, D., Berry, L., Kasman, I., Koeppen, H., Rice, K., Yang, N.-Y., et al. (2012) · Cancer Research · doi:10.1158/0008-5472.can-11-1515 · Cited by 242

TOR Mutations Confer Rapamycin Resistance by Preventing Interaction with FKBP12-Rapamycin

Lorenz, M. C., & Heitman, J. (1995) · Journal of Biological Chemistry · doi:10.1074/jbc.270.46.27531 · Cited by 238

A Phase II Study of PD-0325901, an Oral MEK Inhibitor, in Previously Treated Patients with Advanced Non–Small Cell Lung Cancer

Haura, E. B., Ricart, A. D., Larson, T. G., Stella, P. J., Bazhenova, L., Miller, V. A., Cohen, R. B., Eisenberg, P. D., Selaru, P., Wilner, K. D., et al. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-1920 · Cited by 237

The autophagic tumor stroma model of cancer: Role of oxidative stress and ketone production in fueling tumor cell metabolism

Pavlides, S., Tsirigos, A., Migneco, G., Whitaker-Menezes, D., Chiavarina, B., Flomenberg, N., Frank, P. G., Casimiro, M. C., Wang, C., Pestell, R. G., et al. (2010) · Cell Cycle · doi:10.4161/cc.9.17.12721 · Cited by 235

Propranolol potentiates the anti-angiogenic effects and anti-tumor efficacy of chemotherapy agents: implication in breast cancer treatment

Pasquier, E., Ciccolini, J., Carre, M., Giacometti, S., Fanciullino, R., Pouchy, C., Montero, M.-P., Serdjebi, C., Kavallaris, M., & André, N. (2011) · Oncotarget · doi:10.18632/oncotarget.343 · Cited by 234

GDC-0980 Is a Novel Class I PI3K/mTOR Kinase Inhibitor with Robust Activity in Cancer Models Driven by the PI3K Pathway

Wallin, J. J., Edgar, K. A., Guan, J., Berry, M., Prior, W. W., Lee, L., Lesnick, J. D., Lewis, C., Nonomiya, J., Pang, J., et al. (2011) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-11-0446 · Cited by 229

Akt inhibitors in clinical development for the treatment of cancer

Pal, S. K., Reckamp, K., Yu, H., & Figlin, R. A. (2010) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.2010.520701 · Cited by 226

HIF1-alpha functions as a tumor promoter in cancer-associated fibroblasts, and as a tumor suppressor in breast cancer cells: Autophagy drives compartment-specific oncogenesis

Chiavarina, B., Whitaker-Menezes, D., Migneco, G., Martinez-Outschoorn, U. E., Pavlides, S., Howell, A., Tanowitz, H. B., Casimiro, M. C., Wang, C., Pestell, R. G., et al. (2010) · Cell Cycle · doi:10.4161/cc.9.17.12908 · Cited by 222

Mammalian target of rapamycin (mTOR) inhibition activates phosphatidylinositol 3-kinase/Akt by up-regulating insulin-like growth factor-1 receptor signaling in acute myeloid leukemia: rationale for therapeutic inhibition of both pathways

Tamburini, J., Chapuis, N., Bardet, V., Park, S., Sujobert, P., Willems, L., Ifrah, N., Dreyfus, F., Mayeux, P., Lacombe, C., et al. (2008) · Blood · doi:10.1182/blood-2007-03-080796 · Cited by 221

Tracking the intermediate stages of epithelial-mesenchymal transition in epithelial stem cells and cancer

Jordan, N. V., Johnson, G. L., & Abell, A. N. (2011) · Cell Cycle · doi:10.4161/cc.10.17.17188 · Cited by 220

Rapamycin-Sensitive Pathway Regulates Mitochondrial Membrane Potential, Autophagy, and Survival in Irradiated MCF-7 Cells

Paglin, S., Lee, N.-Y., Nakar, C., Fitzgerald, M., Plotkin, J., Deuel, B., Hackett, N., McMahill, M., Sphicas, E., Lampen, N., et al. (2005) · Cancer Research · doi:10.1158/0008-5472.can-05-1083 · Cited by 220

Discovery of 9-(6-Aminopyridin-3-yl)-1-(3-(trifluoromethyl)phenyl)benzo[h][1,6]naphthyridin-2(1 H)-one (Torin2) as a Potent, Selective, and Orally Available Mammalian Target of Rapamycin (mTOR) Inhibitor for Treatment of Cancer

Liu, Q., Wang, J., Kang, S. A., Thoreen, C. C., Hur, W., Ahmed, T., Sabatini, D. M., & Gray, N. S. (2011) · Journal of Medicinal Chemistry · doi:10.1021/jm101520v · Cited by 219

CRAF inhibition induces apoptosis in melanoma cells with non-V600E BRAF mutations

Smalley, K. S. M., Xiao, M., Villanueva, J., Nguyen, T. K., Flaherty, K. T., Letrero, R., Van Belle, P., Elder, D. E., Wang, Y., Nathanson, K. L., et al. (2009) · Oncogene · doi:10.1038/onc.2008.362 · Cited by 216

Metformin against TGFβ-induced epithelial-to-mesenchymal transition (EMT): From cancer stem cells to aging-associated fibrosis

Cufí, S., Vazquez-Martin, A., Oliveras-Ferraros, C., Martin-Castillo, B., Joven, J., & Menendez, J. A. (2010) · Cell Cycle · doi:10.4161/cc.9.22.14048 · Cited by 216

Antitumor Activity of BRAF Inhibitor Vemurafenib in Preclinical Models of BRAF-Mutant Colorectal Cancer

Yang, H., Higgins, B., Kolinsky, K., Packman, K., Bradley, W. D., Lee, R. J., Schostack, K., Simcox, M. E., Kopetz, S., Heimbrook, D., et al. (2012) · Cancer Research · doi:10.1158/0008-5472.can-11-2941 · Cited by 216

Increased MAPK Expression and Activity in Primary Human Hepatocellular Carcinoma

Schmidt, C. M., McKillop, I. H., Cahill, P. A., & Sitzmann, J. V. (1997) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.1997.6840 · Cited by 212

PI3K-targeted therapy can be evaded by gene amplification along the MYC-eukaryotic translation initiation factor 4E (eIF4E) axis

Ilic, N., Utermark, T., Widlund, H. R., & Roberts, T. M. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1108237108 · Cited by 211

ERK Inhibition Overcomes Acquired Resistance to MEK Inhibitors

Hatzivassiliou, G., Liu, B., O'Brien, C., Spoerke, J. M., Hoeflich, K. P., Haverty, P. M., Soriano, R., Forrest, W. F., Heldens, S., Chen, H., et al. (2012) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-11-1010 · Cited by 211

Rapamycin Resistance Tied to Defective Regulation of p27 Kip1

Luo, Y., Marx, S. O., Kiyokawa, H., Koff, A., Massagué, J., & Marks, A. R. (1996) · Molecular and Cellular Biology · doi:10.1128/mcb.16.12.6744 · Cited by 210

Amplification of the Driving Oncogene, KRAS or BRAF , Underpins Acquired Resistance to MEK1/2 Inhibitors in Colorectal Cancer Cells

Little, A. S., Balmanno, K., Sale, M. J., Newman, S., Dry, J. R., Hampson, M., Edwards, P. A. W., Smith, P. D., & Cook, S. J. (2011) · Science Signaling · doi:10.1126/scisignal.2001752 · Cited by 210

Beyond Rapalog Therapy: Preclinical Pharmacology and Antitumor Activity of WYE-125132, an ATP-Competitive and Specific Inhibitor of mTORC1 and mTORC2

Yu, K., Shi, C., Toral-Barza, L., Lucas, J., Shor, B., Kim, J. E., Zhang, W.-G., Mahoney, R., Gaydos, C., Tardio, L., et al. (2010) · Cancer Research · doi:10.1158/0008-5472.can-09-2340 · Cited by 206

Pim and Akt oncogenes are independent regulators of hematopoietic cell growth and survival

Hammerman, P. S., Fox, C. J., Birnbaum, M. J., & Thompson, C. B. (2005) · Blood · doi:10.1182/blood-2004-09-3706 · Cited by 205

Metformin regulates breast cancer stem cello ntogeny by transcriptional regulation of the epithelial-mesenchymal transition (EMT) status

Vazquez-Martin, A., Oliveras-Ferraros, C., Cufí, S., Del Barco, S., Martin-Castillo, B., & Menendez, J. A. (2010) · Cell Cycle · doi:10.4161/cc.9.18.13131 · Cited by 205

Targeting the translational apparatus to improve leukemia therapy: roles of the PI3K/PTEN/Akt/mTOR pathway

Martelli, A. M., Evangelisti, C., Chappell, W., Abrams, S. L., Bäsecke, J., Stivala, F., Donia, M., Fagone, P., Nicoletti, F., Libra, M., et al. (2011) · Leukemia · doi:10.1038/leu.2011.46 · Cited by 204

Preclinical Characterization of OSI-027, a Potent and Selective Inhibitor of mTORC1 and mTORC2: Distinct from Rapamycin

Bhagwat, S. V., Gokhale, P. C., Crew, A. P., Cooke, A., Yao, Y., Mantis, C., Kahler, J., Workman, J., Bittner, M., Dudkin, L., et al. (2011) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-10-1099 · Cited by 198

A Dual Phosphoinositide-3-Kinase α/mTOR Inhibitor Cooperates with Blockade of Epidermal Growth Factor Receptor in PTEN -Mutant Glioma

Fan, Q.-W., Cheng, C. K., Nicolaides, T. P., Hackett, C. S., Knight, Z. A., Shokat, K. M., & Weiss, W. A. (2007) · Cancer Research · doi:10.1158/0008-5472.can-07-2154 · Cited by 192

Targeting Eukaryotic Translation Initiation Factor 4E (eIF4E) in Cancer

Hsieh, A. C., & Ruggero, D. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-0433 · Cited by 186

The Pim kinases control rapamycin-resistant T cell survival and activation

Fox, C. J., Hammerman, P. S., & Thompson, C. B. (2005) · The Journal of Experimental Medicine · doi:10.1084/jem.20042020 · Cited by 185

RDEA119/BAY 869766: A Potent, Selective, Allosteric Inhibitor of MEK1/2 for the Treatment of Cancer

Iverson, C., Larson, G., Lai, C., Yeh, L.-T., Dadson, C., Weingarten, P., Appleby, T., Vo, T., Maderna, A., Vernier, J.-M., et al. (2009) · Cancer Research · doi:10.1158/0008-5472.can-09-0679 · Cited by 183

Enhanced radiation damage of tumor vasculature by mTOR inhibitors

Shinohara, E. T., Cao, C., Niermann, K., Mu, Y., Zeng, F., Hallahan, D. E., & Lu, B. (2005) · Oncogene · doi:10.1038/sj.onc.1208715 · Cited by 183

Critical roles for mTORC2- and rapamycin-insensitive mTORC1-complexes in growth and survival of BCR-ABL-expressing leukemic cells

Carayol, N., Vakana, E., Sassano, A., Kaur, S., Goussetis, D. J., Glaser, H., Druker, B. J., Donato, N. J., Altman, J. K., Barr, S., et al. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1005114107 · Cited by 180

Antitumor Efficacy of the Novel RAF Inhibitor GDC-0879 Is Predicted by BRAFV600E Mutational Status and Sustained Extracellular Signal-Regulated Kinase/Mitogen-Activated Protein Kinase Pathway Suppression

Hoeflich, K. P., Herter, S., Tien, J., Wong, L., Berry, L., Chan, J., O'Brien, C., Modrusan, Z., Seshagiri, S., Lackner, M., et al. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-3563 · Cited by 174

Inhibition of Phosphorylation of BAD and Raf-1 by Akt Sensitizes Human Ovarian Cancer Cells to Paclitaxel

Mabuchi, S., Ohmichi, M., Kimura, A., Hisamoto, K., Hayakawa, J., Nishio, Y., Adachi, K., Takahashi, K., Arimoto-Ishida, E., Nakatsuji, Y., et al. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m204042200 · Cited by 174

Targeting the mTOR kinase domain: the second generation of mTOR inhibitors

Zhang, Y.-J., Duan, Y., & Zheng, X. F. S. (2011) · Drug Discovery Today · doi:10.1016/j.drudis.2011.02.008 · Cited by 173

RB-pathway disruption in breast cancer: Differential association with disease subtypes, disease-specific prognosis and therapeutic response

Ertel, A., Dean, J. L., Rui, H., Liu, C., Witkiewicz, A., Knudsen, K. E., & Knudsen, E. S. (2010) · Cell Cycle · doi:10.4161/cc.9.20.13454 · Cited by 173

Antitumor Efficacy of PKI-587, a Highly Potent Dual PI3K/mTOR Kinase Inhibitor

Mallon, R., Feldberg, L. R., Lucas, J., Chaudhary, I., Dehnhardt, C., Santos, E. D., Chen, Z., dos Santos, O., Ayral-Kaloustian, S., Venkatesan, A., et al. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-1694 · Cited by 172

Therapeutic resistance resulting from mutations in Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR signaling pathways

McCubrey, J. A., Steelman, L. S., Kempf, C. R., Chappell, W. H., Abrams, S. L., Stivala, F., Malaponte, G., Nicoletti, F., Libra, M., Bäsecke, J., et al. (2011) · Journal of Cellular Physiology · doi:10.1002/jcp.22647 · Cited by 171

Targeted therapy for hepatocellular carcinoma: novel agents on the horizon

Cervello, M., McCubrey, J. A., Cusimano, A., Lampiasi, N., Azzolina, A., & Montalto, G. (2012) · Oncotarget · doi:10.18632/oncotarget.466 · Cited by 170

The HSP90 Inhibitor XL888 Overcomes BRAF Inhibitor Resistance Mediated through Diverse Mechanisms

Paraiso, K. H. T., Haarberg, H. E., Wood, E., Rebecca, V. W., Chen, Y. A., Xiang, Y., Ribas, A., Lo, R. S., Weber, J. S., Sondak, V. K., et al. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-2612 · Cited by 169

Advances in the Development of Cancer Therapeutics Directed against the RAS-Mitogen-Activated Protein Kinase Pathway

Sebolt-Leopold, J. S. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-0333 · Cited by 167

Dual Inhibition of Akt/Mammalian Target of Rapamycin Pathway by Nanoparticle Albumin-Bound –Rapamycin and Perifosine Induces Antitumor Activity in Multiple Myeloma

Cirstea, D., Hideshima, T., Rodig, S., Santo, L., Pozzi, S., Vallet, S., Ikeda, H., Perrone, G., Gorgun, G., Patel, K., et al. (2010) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-09-0763 · Cited by 167

Activity of the Novel Dual Phosphatidylinositol 3-Kinase/Mammalian Target of Rapamycin Inhibitor NVP-BEZ235 against T-Cell Acute Lymphoblastic Leukemia

Chiarini, F., Grimaldi, C., Ricci, F., Tazzari, P. L., Evangelisti, C., Ognibene, A., Battistelli, M., Falcieri, E., Melchionda, F., Pession, A., et al. (2010) · Cancer Research · doi:10.1158/0008-5472.can-10-1814 · Cited by 166

A chemical-genetic screen reveals a mechanism of resistance to PI3K inhibitors in cancer

Muellner, M. K., Uras, I. Z., Gapp, B. V., Kerzendorfer, C., Smida, M., Lechtermann, H., Craig-Mueller, N., Colinge, J., Duernberger, G., & Nijman, S. M. B. (2011) · Nature Chemical Biology · doi:10.1038/nchembio.695 · Cited by 165

Dual Inhibition of PI3K and mTORC1/2 Signaling by NVP-BEZ235 as a New Therapeutic Strategy for Acute Myeloid Leukemia

Chapuis, N., Tamburini, J., Green, A. S., Vignon, C., Bardet, V., Neyret, A., Pannetier, M., Willems, L., Park, S., Macone, A., et al. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-1102 · Cited by 164

A brief history of melanoma: from mummies to mutations

Rebecca, V. W., Sondak, V. K., & Smalley, K. S. M. (2012) · Melanoma Research · doi:10.1097/cmr.0b013e328351fa4d · Cited by 163

PF-04691502, a Potent and Selective Oral Inhibitor of PI3K and mTOR Kinases with Antitumor Activity

Yuan, J., Mehta, P. P., Yin, M.-J., Sun, S., Zou, A., Chen, J., Rafidi, K., Feng, Z., Nickel, J., Engebretsen, J., et al. (2011) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-11-0185 · Cited by 163

Mechanisms of mTOR inhibitor resistance in cancer therapy

Carew, J. S., Kelly, K. R., & Nawrocki, S. T. (2011) · Targeted Oncology · doi:10.1007/s11523-011-0167-8 · Cited by 161

Phase I Study of Everolimus in Pediatric Patients With Refractory Solid Tumors

Fouladi, M., Laningham, F., Wu, J., O'Shaughnessy, M. A., Molina, K., Broniscer, A., Spunt, S. L., Luckett, I., Stewart, C. F., Houghton, P. J., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2007.11.4017 · Cited by 160

Sorafenib therapy in advanced hepatocellular carcinoma: the SHARP trial

Rimassa, L., & Santoro, A. (2009) · Expert Review of Anticancer Therapy · doi:10.1586/era.09.41 · Cited by 159

Chemotherapy and Targeted Therapy Combinations in Advanced Melanoma

Flaherty, K. T. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-2505 · Cited by 159

First-in-class, first-in-human phase I results of targeted agents: Highlights of the 2008 American Society of Clinical Oncology meeting

Molckovsky, A., & Siu, L. L. (2008) · Journal of Hematology & Oncology · doi:10.1186/1756-8722-1-20 · Cited by 159

Molecular mechanisms of sorafenib action in liver cancer cells

Cervello, M., Bachvarov, D. R., Lampiasi, N., Cusimano, A., Azzolina, A., McCubrey, J. A., & Montalto, G. (2012) · Cell Cycle · doi:10.4161/cc.21193 · Cited by 158

Gatekeeper Mutations Mediate Resistance to BRAF-Targeted Therapies

Whittaker, S. R., Kirk, R., Hayward, R., Zambon, A., Virós, A., Cantariño, N., Affolter, A., Nourry, A., Niculescu‐Duvaz, D., Springer, C. J., et al. (2010) · Science Translational Medicine · doi:10.1126/scitranslmed.3000758 · Cited by 158

The autophagic tumor stroma model of cancer or “battery-operated tumor growth”: A simple solution to the autophagy paradox

Martinez‐Outschoorn, U., Whitaker‐Menezes, D., Pavlides, S., Chiavarina, B., Bonuccelli, G., Trimmer, C., Tsirigos, A., Migneco, G., Witkiewicz, A. K., Balliet, R. M., et al. (2010) · Cell Cycle · doi:10.4161/cc.9.21.13817 · Cited by 158

Inhibition of PI3K/mTOR pathways in glioblastoma and implications for combination therapy with temozolomide

Prasad, G., Sottero, T. L., Yang, X., Mueller, S., James, C. D., Weiss, W. A., Polley, M. Y., Ozawa, T., Berger, M. S., Aftab, D. T., et al. (2011) · Neuro-Oncology · doi:10.1093/neuonc/noq193 · Cited by 156

Transcriptional evidence for the "Reverse Warburg Effect" in human breast cancer tumor stroma and metastasis: Similarities with oxidative stress, inflammation, Alzheimer's disease, and "Neuron-Glia Metabolic Coupling"

Pavlides, S., Tsirigos, A., Vera, I., Flomenberg, N., Frank, P. G., Casimiro, M. C., Wang, C., Pestell, R. G., Martinez‐Outschoorn, U., Howell, A., et al. (2010) · Aging · doi:10.18632/aging.100134 · Cited by 155

A selective inhibitor of the p110δ isoform of PI 3-kinase inhibits AML cell proliferation and survival and increases the cytotoxic effects of VP16

Billottet, C., Grandage, V., Gale, R. E., Quattropani, A., Rommel, C., Vanhaesebroeck, B., & Khwaja, A. (2006) · Oncogene · doi:10.1038/sj.onc.1209670 · Cited by 155

Mammalian Target of Rapamycin Pathway Activity in Hepatocellular Carcinomas of Patients Undergoing Liver Transplantation

Sieghart, W., Fuereder, T., Schmid, K., Cejka, D., Werzowa, J. M., Wrba, F., Wang, X., Gruber, D., Rasoul‐Rockenschaub, S., Peck‐Radosavljevic, M., et al. (2007) · Transplantation · doi:10.1097/01.tp.0000252780.42104.95 · Cited by 154

Phosphatidylinositol 3-kinase/Akt signaling in the response of vascular endothelium to ionizing radiation.

Edwards, E., Geng, L., Tan, J., Onishko, H. M., Donnelly, E. F., & Hallahan, D. E. (2002) · PubMed · Cited by 152

PI3Kδ inhibitor, GS-1101 (CAL-101), attenuates pathway signaling, induces apoptosis, and overcomes signals from the microenvironment in cellular models of Hodgkin lymphoma

Meadows, S. A., Vega, F., Kashishian, A., Johnson, D., Diehl, V., Miller, L. L., Younes, A., & Lannutti, B. J. (2011) · Blood · doi:10.1182/blood-2011-10-386763 · Cited by 152

Safety and anti-tumor activity of sorafenib (Nexavar®) in combination with other anti-cancer agents: a review of clinical trials

Takimoto, C. H. M., & Awada, A. H. (2007) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-007-0639-9 · Cited by 152

First-in-Human, Phase I Dose-Escalation Study of the Safety, Pharmacokinetics, and Pharmacodynamics of RO5126766, a First-in-Class Dual MEK/RAF Inhibitor in Patients with Solid Tumors

Martinez‐García, M., Banerji, U., Albanell, J., Bahleda, R., Dolly, S. O., Kraeber‐Bodéré, F., Rojo, F., Routier, É., Guarin, E., Xu, Z., et al. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-0742 · Cited by 152

Targeting Autophagy Addiction in Cancer

Mancias, J. D., & Kimmelman, A. C. (2011) · Oncotarget · doi:10.18632/oncotarget.384 · Cited by 152

Structure-Guided Design of Potent and Selective Pyrimidylpyrrole Inhibitors of Extracellular Signal-Regulated Kinase (ERK) Using Conformational Control

Aronov, A. M., Tang, Q., Martínez-Botella, G., Bemis, G. W., Cao, J., Chen, G., Ewing, N. P., Ford, P. J., Germann, U. A., Green, J., et al. (2009) · Journal of Medicinal Chemistry · doi:10.1021/jm900630q · Cited by 152

Targeted inhibition of the extracellular signal-regulated kinase kinase pathway with AZD6244 (ARRY-142886) in the treatment of hepatocellular carcinoma

Huynh, H. T., Soo, K. C., Chow, P. K. H., & Tran, E. (2007) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-06-0436 · Cited by 150

NVP-BEZ235 as a New Therapeutic Option for Sarcomas

Manara, M. C., Nicoletti, G., Zambelli, D., Ventura, S., Guerzoni, C., Landuzzi, L., Lollini, P., Maira, S.-M., Garcı́a-Echeverrı́a, C., Mercuri, M., et al. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-0816 · Cited by 149

Processing of O6-methylguanine into DNA double-strand breaks requires two rounds of replication whereas apoptosis is also induced in subsequent cell cycles

Quirós, S., Roos, W. P., & Kaina, B. (2010) · Cell Cycle · doi:10.4161/cc.9.1.10363 · Cited by 144

Effect of Rapamycin Alone and in Combination with Sorafenib in an Orthotopic Model of Human Hepatocellular Carcinoma

Wang, Z., Zhou, J. P., Fan, J., Qiu, S., Yao, Y., Huang, X., & Tang, Z. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-4774 · Cited by 144

PIM1 Protein Kinase regulates PRAS40 phosphorylation and mTOR activity in FDCP1 cells

Zhang, F., Beharry, Z. M., Harris, T. E., Lilly, M. B., Smith, C. D., Mahajan, S., & Kraft, A. S. (2009) · Cancer Biology & Therapy · doi:10.4161/cbt.8.9.8210 · Cited by 143

Melanoma cells show a heterogeneous range of sensitivity to ionizing radiation and are radiosensitized by inhibition of B-RAF with PLX-4032

Sambade, M. J., Peters, E. C., Thomas, N. E., Kaufmann, W. K., Kimple, R. J., & Shields, J. M. (2011) · Radiotherapy and Oncology · doi:10.1016/j.radonc.2010.12.017 · Cited by 142

Exploring long-term protection of normal human fibroblasts and epithelial cells from chemotherapy in cell culture

Apontes, P., Leontieva, O. V., Demidenko, Z. N., Li, F., & Blagosklonny, M. V. (2011) · Oncotarget · doi:10.18632/oncotarget.248 · Cited by 141

The novel Akt inhibitor, perifosine, induces caspase-dependent apoptosis and downregulates P-glycoprotein expression in multidrug-resistant human T-acute leukemia cells by a JNK-dependent mechanism

Chiarini, F., Sole, M. D., Mongiorgi, S., Gaboardi, G. C., Cappellini, A., Mantovani, I., Follo, M. Y., McCubrey, J. A., & Martelli, A. M. (2008) · Leukemia · doi:10.1038/leu.2008.79 · Cited by 139

Potent and Selective Disruption of Protein Kinase D Functionality by a Benzoxoloazepinolone

Sharlow, E. R., Giridhar, K. V., LaValle, C. R., Chen, J., Leimgruber, S., Barrett, R., Bravo‐Altamirano, K., Wipf, P., Lazo, J. S., & Wang, Q. J. (2008) · Journal of Biological Chemistry · doi:10.1074/jbc.m805358200 · Cited by 139

Cellular and in vivo activity of a novel PI3K inhibitor, PX-866, against human glioblastoma

Koul, D., Shen, R., Kim, Y., Kondo, Y., Lu, Y., Bankson, J. A., Ronen, S. M., Kirkpatrick, D. L., Powis, G., & Yung, W. K. A. (2010) · Neuro-Oncology · doi:10.1093/neuonc/nop058 · Cited by 130

B55β-Associated PP2A Complex Controls PDK1-Directed Myc Signaling and Modulates Rapamycin Sensitivity in Colorectal Cancer

Tan, J. Y., Lee, P. L., Li, Z., Jiang, X., Lim, Y. C., Hooi, S. C., & Yu, Q. (2010) · Cancer Cell · doi:10.1016/j.ccr.2010.10.021 · Cited by 127

Blockade of the MEK/ERK signalling cascade by AS703026, a novel selective MEK1/2 inhibitor, induces pleiotropic anti‐myeloma activity in vitro and in vivo

Kım, K., Kong, S., Fulciniti, M., Li, X., Song, W., Nahar, S., Burger, P., Rumizen, M. J., Podar, K., Chauhan, D., et al. (2010) · British Journal of Haematology · doi:10.1111/j.1365-2141.2010.08127.x · Cited by 126

Discovery of TAK-733, a potent and selective MEK allosteric site inhibitor for the treatment of cancer

Dong, Q., Dougan, D. R., Gong, X., Halkowycz, P., Jin, B., Kanouni, T., O’Connell, S. M., Scorah, N., Shi, L., Wallace, M. B., et al. (2011) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2011.01.071 · Cited by 124

Cytokine production and inflammation drive autophagy in the tumor microenvironment: Role of stromal caveolin-1 as a key regulator

Martinez‐Outschoorn, U., Whitaker‐Menezes, D., Zhao, L., Flomenberg, N., Howell, A., Pestell, R. G., Lisanti, M. P., & Sotgia, F. (2011) · Cell Cycle · doi:10.4161/cc.10.11.15674 · Cited by 124

The Pim protein kinases regulate energy metabolism and cell growth

Beharry, Z. M., Mahajan, S., Zemskova, M., Lin, Y.-W., Tholanikunnel, B. G., Xia, Z., Smith, C. D., & Kraft, A. S. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1013214108 · Cited by 124

Two hits are better than one: targeting both phosphatidylinositol 3-kinase and mammalian target of rapamycin as a therapeutic strategy for acute leukemia treatment

Martelli, A. M., Chiarini, F., Evangelisti, C., Cappellini, A., Buontempo, F., Bressanin, D., Fini, M., & McCubrey, J. A. (2012) · Oncotarget · doi:10.18632/oncotarget.477 · Cited by 122

The novel orally bioavailable inhibitor of phosphoinositol-3-kinase and mammalian target of rapamycin, NVP-BEZ235, inhibits growth and proliferation in multiple myeloma

Baumann, P., Mandl–Weber, S., Oduncu, F. S., & Schmidmaier, R. (2008) · Experimental Cell Research · doi:10.1016/j.yexcr.2008.11.007 · Cited by 121

Dual Inhibition of Class IA Phosphatidylinositol 3-Kinase and Mammalian Target of Rapamycin as a New Therapeutic Option for T-Cell Acute Lymphoblastic Leukemia

Chiarini, F., Falà, F., Tazzari, P. L., Ricci, F., Astolfi, A., Pession, A., Pagliaro, P., McCubrey, J. A., & Martelli, A. M. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-4884 · Cited by 120

Resistance to MEK inhibitors: should we co-target upstream?

Poulikakos, P. I., & Solit, D. B. (2011) · Science Signaling · doi:10.1126/scisignal.2001948 · Cited by 119

Vorinostat Enhances the Activity of Temsirolimus in Renal Cell Carcinoma Through Suppression of Survivin Levels

Mahalingam, D., Medina, E. C., Esquivel, J., Espitia, C. M., Smith, S. A., Oberheu, K., Swords, R. T., Kelly, K. R., Mita, M. M., Mita, A. C., et al. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-1385 · Cited by 119

Restoring p53 active conformation by zinc increases the response of mutant p53 tumor cells to anticancer drugs

Puca, R., Nardinocchi, L., Porru, M., Simon, A. J., Rechavi, G., Leonetti, C., Givol, D., & D’Orazi, G. (2011) · Cell Cycle · doi:10.4161/cc.10.10.15642 · Cited by 117

Targeting the Phosphatidylinositol 3-Kinase/Akt/Mammalian Target of Rapamycin Signaling Network in Cancer Stem Cells

Martelli, A. M., Evangelisti, C., Follo, M., Ramazzotti, G., Fini, M., Giardino, R., Manzoli, L., McCubrey, J. A., & Cocco, L. (2011) · Current Medicinal Chemistry · doi:10.2174/092986711796011201 · Cited by 116

Synergistic inhibition of human melanoma proliferation by combination treatment with B-Raf inhibitor BAY43-9006 and mTOR inhibitor Rapamycin

Molhoek, K. R., Brautigan, D. L., & Slingluff, C. L. (2005) · Journal of Translational Medicine · doi:10.1186/1479-5876-3-39 · Cited by 115

Fasting and differential chemotherapy protection in patients

Raffaghello, L., Safdie, F. M., Bianchi, G., Dorff, T. B., Fontana, L., & Longo, V. D. (2010) · Cell Cycle · doi:10.4161/cc.9.22.13954 · Cited by 114

RB1 and p53 at the crossroad of EMT and triple-negative breast cancer

Jiang, Z., Jones, R. A., Liu, J. C., Deng, T., Robinson, T., Chung, P. E. D., Wang, S., Herschkowitz, J. I., Egan, S., Perou, C., et al. (2011) · Cell Cycle · doi:10.4161/cc.10.10.15703 · Cited by 114

Mechanisms of acquired resistance to ERK1/2 pathway inhibitors

Little, A. S., Smith, P. D., & Cook, S. J. (2012) · Oncogene · doi:10.1038/onc.2012.160 · Cited by 113

Targeting Mitogen-Activated Protein Kinase/Extracellular Signal–Regulated Kinase Kinase in the Mutant (V600E) B-Raf Signaling Cascade Effectively Inhibits Melanoma Lung Metastases

Sharma, A. K., Tran, M. A., Liang, S., Sharma, A. K., Amin, S., Smith, C. D., Dong, C., & Robertson, G. P. (2006) · Cancer Research · doi:10.1158/0008-5472.can-06-0809 · Cited by 112

Palomid 529, a Novel Small-Molecule Drug, Is a TORC1/TORC2 Inhibitor That Reduces Tumor Growth, Tumor Angiogenesis, and Vascular Permeability

Xue, Q., Hopkins, B. D., Perruzzi, C. A., Udayakumar, D., Sherris, D., & Benjamin, L. E. (2008) · Cancer Research · doi:10.1158/0008-5472.can-08-2058 · Cited by 112

Perspectives on inhibiting mTOR as a future treatment strategy for hematological malignancies

Chapuis, N., Tamburini, J., Green, A. S., Willems, L., Bardet, V., Park, S., Lacombe, C., Mayeux, P., & Bouscary, D. (2010) · Leukemia · doi:10.1038/leu.2010.170 · Cited by 109

Simultaneous Inhibition of PDK1/AKT and Fms-Like Tyrosine Kinase 3 Signaling by a Small-Molecule KP372-1 Induces Mitochondrial Dysfunction and Apoptosis in Acute Myelogenous Leukemia

Zeng, Z., Samudio, I. J., Zhang, W., Estrov, Z. E., Pelicano, H., Harris, D., Frolova, O., Hail, N., Chen, W., Kornblau, S. M., et al. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-1278 · Cited by 109

PI3K and mTOR inhibitors — a new generation of targeted anticancer agents

Brachmann, S. M., Fritsch, C. M., Maira, S.-M., & García-Echeverría, C. (2009) · Current Opinion in Cell Biology · doi:10.1016/j.ceb.2008.12.011 · Cited by 108

AMP-dependent kinase/mammalian target of rapamycin complex 1 signaling in T-cell acute lymphoblastic leukemia: therapeutic implications

Grimaldi, C., Chiarini, F., Tabellini, G., Ricci, F., Tazzari, P. L., Battistelli, M., Falcieri, E., Bortul, R., Melchionda, F., Iacobucci, I., et al. (2011) · Leukemia · doi:10.1038/leu.2011.269 · Cited by 104

Progress in the Preclinical Discovery and Clinical Development of Class I and Dual Class I/IV Phosphoinositide 3-Kinase (PI3K) Inhibitors

Shuttleworth, S. J., Silva, F. A., Cecil, A., Tomassi, C., Hill, T., Raynaud, F. I., Clarke, P. A., & Workman, P. (2011) · Current Medicinal Chemistry · doi:10.2174/092986711796011229 · Cited by 104

Autophagy suppression promotes apoptotic cell death in response to inhibition of the PI3K—mTOR pathway in pancreatic adenocarcinoma

Mirzoeva, O. K., Hann, B. C., Hom, Y. K., Debnath, J., Aftab, D. T., Shokat, K. M., & Korn, W. M. (2011) · Journal of Molecular Medicine · doi:10.1007/s00109-011-0774-y · Cited by 102

Multiple anticancer effects of blocking MEK-ERK signaling in hepatocellular carcinoma1

Wiesenauer, C. A., Yip-Schneider, M., Wang, Y., & Schmidt, C. M. (2004) · Journal of the American College of Surgeons · doi:10.1016/j.jamcollsurg.2003.10.004 · Cited by 101

Yeast-like chronological senescence in mammalian cells: phenomenon, mechanism and pharmacological suppression

Leontieva, O. V., & Blagosklonny, M. V. (2011) · Aging · doi:10.18632/aging.100402 · Cited by 101

Targeted cellular metabolism for cancer chemotherapy with recombinant arginine-degrading enzymes

Kuo, M. T., Savaraj, N., & Feun, L. G. (2010) · Oncotarget · doi:10.18632/oncotarget.135 · Cited by 100

PKI-587 and Sorafenib Targeting PI3K/AKT/mTOR and Ras/Raf/MAPK Pathways Synergistically Inhibit HCC Cell Proliferation

Gedaly, R., Angulo, P., Hundley, J. C., Daily, M. F., Chen, C., & Evers, B. M. (2011) · Journal of Surgical Research · doi:10.1016/j.jss.2011.10.045 · Cited by 100

4E-binding Proteins, the Suppressors of Eukaryotic Initiation Factor 4E, Are Down-regulated in Cells with Acquired or Intrinsic Resistance to Rapamycin

Dilling, M. B., Germain, G. S., Dudkin, L., Jayaraman, A. L., Zhang, X., Harwood, F. C., & Houghton, P. J. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m110782200 · Cited by 98

Chk1 inhibition after replicative stress activates a double strand break response mediated by ATM and DNA-dependent protein kinase

McNeely, S., Conti, C., Sheikh, T. N., et al. (2010) · Cell Cycle · doi:10.4161/cc.9.5.10935 · Cited by 98

Wnt/β-catenin signaling in cancers and targeted therapies

Yu, F., Yu, C., Li, F., Zuo, Y., Wang, Y., Yao, L., Wu, C., Wang, C., & Ye, L. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00701-5 · Cited by 734

Central role of Snail1 in the regulation of EMT and resistance in cancer: a target for therapeutic intervention

Kaufhold, S., & Bonavida, B. (2014) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/preaccept-1929235422128885 · Cited by 469

Exosomal levels of miRNA-21 from cerebrospinal fluids associated with poor prognosis and tumor recurrence of glioma patients

Shi, R., Wang, P.-Y., Li, X.-Y., Chen, J.-X., Li, Y., Zhang, X.-Z., Zhang, C.-G., Jiang, T., Li, W.-B., Ding, W., et al. (2015) · Oncotarget · doi:10.18632/oncotarget.4699 · Cited by 285

Targeting GSK3 and Associated Signaling Pathways Involved in Cancer

Duda, P., Akula, S. M., Abrams, S. L., Steelman, L. S., Martelli, A. M., Cocco, L., Ratti, S., Candido, S., Libra, M., Montalto, G., et al. (2020) · Cells · doi:10.3390/cells9051110 · Cited by 284

Mechanism-based cancer therapy: resistance to therapy, therapy for resistance

Ramos, P., & Bentires-Alj, M. (2015) · Oncogene · doi:10.1038/onc.2014.314 · Cited by 272